PHYTOMEDICINE 润色咨询

PHYTOMEDICINE

出版年份:1994 年文章数:2603 投稿命中率: 开通期刊会员,数据随心看

出版周期:Monthly 自引率:2.2% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2122040, encodeId=eb54212204091, content=审稿速度:12.0 | 投稿命中率:50.0<br>偏重的研究方向:中药<br>经验分享:想请问大家,Under Editor Assessment这个状态卡了快一个月了,是什么意思呀,可以发邮件催一下吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fc65556145, createdName=ms4000000742058182, createdTime=Mon Mar 27 11:02:07 CST 2023, time=2023-03-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2198636, encodeId=1943219863695, content=请问proof返回后大概多久online啊,已经大半个月了还没有online🥹, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c368992874, createdName=ms6000000634273240, createdTime=Mon Apr 15 17:05:20 CST 2024, time=2024-04-15, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2139117, encodeId=8f50213911ec7, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肾脏病;中药复方<br>经验分享:请问Proof后多久才能出版呢,已经Proof两周了,没有动静,并且Pre-Online是未Proof版本,上周已邮件咨询过,回复是正在校稿,这快两周过去了,有知道情况的友友吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eab8634806, createdName=ms6000000954293507, createdTime=Fri May 26 09:07:39 CST 2023, time=2023-05-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2177803, encodeId=19a121e7803be, content=让我修了两轮的格式和图片<br>12.25 submitted to journal<br>12.26 under editor assessment, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20240101/570c45f5d7f2451da2e0a51a7b25b479/824b9aa7cdc24982879c3db6cbeb3798.jpg, createdBy=a3422257516, createdName=samtol, createdTime=Thu Dec 28 15:41:53 CST 2023, time=2023-12-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2161515, encodeId=c19f2161515a5, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:中药抗肿瘤<br>经验分享:一审速度比较快,5月投稿,6月收到修改意见,二审、三审速度就非常慢!7月26号根据一审意见返回杂志社,9月18号返回二审意见,只有修改题目一条意见,19号修回后,26号才发邮件告知修改格式,当天修改完提交后,等到10月4日才显示状态改变,10月5日变成under review,发出2个review invitations,1个accept。。。真是太漫长了,感觉编辑1周处理一次稿件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=63b45479551, createdName=ms5000000155404164, createdTime=Sun Oct 08 11:32:31 CST 2023, time=2023-10-08, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=1237955, encodeId=4429123e9555f, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:中药药理;中药复方<br>经验分享:5.30投稿<br>5.31要求提供缩略词,补充后当晚提交了<br>6.6 under review<br>6.22 Required Reviews Completed<br>6.26 revise<br>主编+6个审稿专家,加起来50多个问题,审稿意见非常细节,很注重创新性。还好整体评价比较积极,对文章大框架没什么意见,只给了我3周修改,我还补了一点实验,最后几天写回复写到怀疑人生……<br>7.14 summit<br>7.15 Under Editor Assessment<br>7.24 under review<br>8.2 Required Reviews Completed<br>8.3 Decision in Process<br>8.4 accepted<br>8.6 Proof<br><br>感谢主编和外审专家们!第一次投sci,好多地方都不清楚,每天都快把论坛翻烂了……还好最后顺利接收,写一点我在翻帖子时大家提问多的事情吧:1.Author Agreement:这个在爱思唯尔投稿作者须知那里有个链接能下载,有点不太好找。2.western结果:revise时要求提供原始未裁剪的膜,这个前期做实验的时候需要注意下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=feb46571516, createdName=msyukira, createdTime=Wed Aug 10 23:59:55 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197546, encodeId=6fd1219e54687, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:中药复方<br>经验分享:想问一下各位已投稿的宝子们phytomedicine复方投稿需要提供指纹图谱吗,没有怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=468e9243712, createdName=ms8000002041881019, createdTime=Tue Apr 09 10:23:45 CST 2024, time=2024-04-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2126674, encodeId=3a3521266e454, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:中药复方;代谢病<br>经验分享:2023.02.25 submit<br>2023.03.03 under editor assessment<br>2023.03.09 under review<br>2023.03.19 required reviews completed<br>2023.03.25 revise,审稿人意见都比较积极,算是小修、润色、降重。给了20天修回。<br>2023.04.12 返回<br>2023.04.17 under editor assessment<br>2023.04.18 reviewer invited<br>目前是这种状态,后续再更新状态。<br><br>希望能够顺利接收,总体来讲,审稿人如果审的快的话一个月就可以完成。<br>编辑和杂志都不错,效率其实还行。<br><br>希望能赶在毕业前接收~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54158562904, createdName=ms2000000770833142, createdTime=Tue Apr 18 09:45:29 CST 2023, time=2023-04-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2131405, encodeId=6236213140557, content=想要询问一下以下情况如何解决:<br><br>(X) Author agreement<br>(has to be uploaded as an extra file; Format: MS Word, TIF, EPS, … (not .pdf please!))<br>The author agreement form for this journal with all author signatures is required. The signature of corresponding author is mandatory.<br>(https://www.elsevier.com/__data/promis_misc/710660_aucc_author_agreement.pdf)<br>(X) Format: Acceptable text file formats include MS Word, Word Perfect, RTF, TEX or plain ASCII text. TIF and EPS files are preferred for figures. PDF, DVI and PS files are not acceptable for publishing purposes.<br>(X) Figure legends. Only text; before figures<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57318663160, createdName=ms1000001447770011, createdTime=Wed May 10 14:57:44 CST 2023, time=2023-05-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2130918, encodeId=df56213091879, content=咨询大家一下,投稿出现这些问题,要如何处理呢?<br><br>(X)Figure legends. Only text; before figures<br><br>(X) Figures separately, also at the end of the manuscript have to be uploaded as an extra file (Format: TIF, EPS) without legends<br><br>(X) Reference list according to our journal style.<br>--&gt; In alphabetical order without numbers<br>--&gt; with ABBREVIATED journal titles.<br>(ex. Goto, N., Ueo, T., Fukuda, A., Kawada, K., Sakai, Y., Miyoshi, H., Taketo, M.M., Chiba, T., Seno, H., 2017. Distinct roles of HES1 in normal stem cells and tumor stem-like cells of the intestine. Cancer Res. 77 (13), 3442-3454.)<br><br>(X) All citations in the text should refer to:<br>1. Single author: the author's name (without initials, unless there is ambiguity) and the year of publication;<br>2. Two authors: both authors' names and the year of publication;<br>3. Three or more authors: first author's name followed by 'et al.' and the year of publication.<br>Citations may be made directly (or parenthetically). Groups of references should be listed first alphabetically, then chronologically.<br>Examples: 'as demonstrated (Allan, 2000a, 2000b, 1999; Allan and Jones, 1999).(Kramer et al.,2010). Kramer et al. (2010) have recently shown .…'<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b168663492, createdName=ms7000000863199411, createdTime=Mon May 08 09:20:15 CST 2023, time=2023-05-08, status=1, ipAttribution=江西省)]
    2023-03-27 ms4000000742058182 来自北京

    审稿速度:12.0 | 投稿命中率:50.0
    偏重的研究方向:中药
    经验分享:想请问大家,Under Editor Assessment这个状态卡了快一个月了,是什么意思呀,可以发邮件催一下吗?

    4

    展开4条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2122040, encodeId=eb54212204091, content=审稿速度:12.0 | 投稿命中率:50.0<br>偏重的研究方向:中药<br>经验分享:想请问大家,Under Editor Assessment这个状态卡了快一个月了,是什么意思呀,可以发邮件催一下吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fc65556145, createdName=ms4000000742058182, createdTime=Mon Mar 27 11:02:07 CST 2023, time=2023-03-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2198636, encodeId=1943219863695, content=请问proof返回后大概多久online啊,已经大半个月了还没有online🥹, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c368992874, createdName=ms6000000634273240, createdTime=Mon Apr 15 17:05:20 CST 2024, time=2024-04-15, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2139117, encodeId=8f50213911ec7, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肾脏病;中药复方<br>经验分享:请问Proof后多久才能出版呢,已经Proof两周了,没有动静,并且Pre-Online是未Proof版本,上周已邮件咨询过,回复是正在校稿,这快两周过去了,有知道情况的友友吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eab8634806, createdName=ms6000000954293507, createdTime=Fri May 26 09:07:39 CST 2023, time=2023-05-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2177803, encodeId=19a121e7803be, content=让我修了两轮的格式和图片<br>12.25 submitted to journal<br>12.26 under editor assessment, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20240101/570c45f5d7f2451da2e0a51a7b25b479/824b9aa7cdc24982879c3db6cbeb3798.jpg, createdBy=a3422257516, createdName=samtol, createdTime=Thu Dec 28 15:41:53 CST 2023, time=2023-12-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2161515, encodeId=c19f2161515a5, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:中药抗肿瘤<br>经验分享:一审速度比较快,5月投稿,6月收到修改意见,二审、三审速度就非常慢!7月26号根据一审意见返回杂志社,9月18号返回二审意见,只有修改题目一条意见,19号修回后,26号才发邮件告知修改格式,当天修改完提交后,等到10月4日才显示状态改变,10月5日变成under review,发出2个review invitations,1个accept。。。真是太漫长了,感觉编辑1周处理一次稿件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=63b45479551, createdName=ms5000000155404164, createdTime=Sun Oct 08 11:32:31 CST 2023, time=2023-10-08, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=1237955, encodeId=4429123e9555f, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:中药药理;中药复方<br>经验分享:5.30投稿<br>5.31要求提供缩略词,补充后当晚提交了<br>6.6 under review<br>6.22 Required Reviews Completed<br>6.26 revise<br>主编+6个审稿专家,加起来50多个问题,审稿意见非常细节,很注重创新性。还好整体评价比较积极,对文章大框架没什么意见,只给了我3周修改,我还补了一点实验,最后几天写回复写到怀疑人生……<br>7.14 summit<br>7.15 Under Editor Assessment<br>7.24 under review<br>8.2 Required Reviews Completed<br>8.3 Decision in Process<br>8.4 accepted<br>8.6 Proof<br><br>感谢主编和外审专家们!第一次投sci,好多地方都不清楚,每天都快把论坛翻烂了……还好最后顺利接收,写一点我在翻帖子时大家提问多的事情吧:1.Author Agreement:这个在爱思唯尔投稿作者须知那里有个链接能下载,有点不太好找。2.western结果:revise时要求提供原始未裁剪的膜,这个前期做实验的时候需要注意下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=feb46571516, createdName=msyukira, createdTime=Wed Aug 10 23:59:55 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197546, encodeId=6fd1219e54687, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:中药复方<br>经验分享:想问一下各位已投稿的宝子们phytomedicine复方投稿需要提供指纹图谱吗,没有怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=468e9243712, createdName=ms8000002041881019, createdTime=Tue Apr 09 10:23:45 CST 2024, time=2024-04-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2126674, encodeId=3a3521266e454, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:中药复方;代谢病<br>经验分享:2023.02.25 submit<br>2023.03.03 under editor assessment<br>2023.03.09 under review<br>2023.03.19 required reviews completed<br>2023.03.25 revise,审稿人意见都比较积极,算是小修、润色、降重。给了20天修回。<br>2023.04.12 返回<br>2023.04.17 under editor assessment<br>2023.04.18 reviewer invited<br>目前是这种状态,后续再更新状态。<br><br>希望能够顺利接收,总体来讲,审稿人如果审的快的话一个月就可以完成。<br>编辑和杂志都不错,效率其实还行。<br><br>希望能赶在毕业前接收~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54158562904, createdName=ms2000000770833142, createdTime=Tue Apr 18 09:45:29 CST 2023, time=2023-04-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2131405, encodeId=6236213140557, content=想要询问一下以下情况如何解决:<br><br>(X) Author agreement<br>(has to be uploaded as an extra file; Format: MS Word, TIF, EPS, … (not .pdf please!))<br>The author agreement form for this journal with all author signatures is required. The signature of corresponding author is mandatory.<br>(https://www.elsevier.com/__data/promis_misc/710660_aucc_author_agreement.pdf)<br>(X) Format: Acceptable text file formats include MS Word, Word Perfect, RTF, TEX or plain ASCII text. TIF and EPS files are preferred for figures. PDF, DVI and PS files are not acceptable for publishing purposes.<br>(X) Figure legends. Only text; before figures<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57318663160, createdName=ms1000001447770011, createdTime=Wed May 10 14:57:44 CST 2023, time=2023-05-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2130918, encodeId=df56213091879, content=咨询大家一下,投稿出现这些问题,要如何处理呢?<br><br>(X)Figure legends. Only text; before figures<br><br>(X) Figures separately, also at the end of the manuscript have to be uploaded as an extra file (Format: TIF, EPS) without legends<br><br>(X) Reference list according to our journal style.<br>--&gt; In alphabetical order without numbers<br>--&gt; with ABBREVIATED journal titles.<br>(ex. Goto, N., Ueo, T., Fukuda, A., Kawada, K., Sakai, Y., Miyoshi, H., Taketo, M.M., Chiba, T., Seno, H., 2017. Distinct roles of HES1 in normal stem cells and tumor stem-like cells of the intestine. Cancer Res. 77 (13), 3442-3454.)<br><br>(X) All citations in the text should refer to:<br>1. Single author: the author's name (without initials, unless there is ambiguity) and the year of publication;<br>2. Two authors: both authors' names and the year of publication;<br>3. Three or more authors: first author's name followed by 'et al.' and the year of publication.<br>Citations may be made directly (or parenthetically). Groups of references should be listed first alphabetically, then chronologically.<br>Examples: 'as demonstrated (Allan, 2000a, 2000b, 1999; Allan and Jones, 1999).(Kramer et al.,2010). Kramer et al. (2010) have recently shown .…'<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b168663492, createdName=ms7000000863199411, createdTime=Mon May 08 09:20:15 CST 2023, time=2023-05-08, status=1, ipAttribution=江西省)]
    2024-04-15 ms6000000634273240 来自四川省

    请问proof返回后大概多久online啊,已经大半个月了还没有online🥹

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2122040, encodeId=eb54212204091, content=审稿速度:12.0 | 投稿命中率:50.0<br>偏重的研究方向:中药<br>经验分享:想请问大家,Under Editor Assessment这个状态卡了快一个月了,是什么意思呀,可以发邮件催一下吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fc65556145, createdName=ms4000000742058182, createdTime=Mon Mar 27 11:02:07 CST 2023, time=2023-03-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2198636, encodeId=1943219863695, content=请问proof返回后大概多久online啊,已经大半个月了还没有online🥹, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c368992874, createdName=ms6000000634273240, createdTime=Mon Apr 15 17:05:20 CST 2024, time=2024-04-15, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2139117, encodeId=8f50213911ec7, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肾脏病;中药复方<br>经验分享:请问Proof后多久才能出版呢,已经Proof两周了,没有动静,并且Pre-Online是未Proof版本,上周已邮件咨询过,回复是正在校稿,这快两周过去了,有知道情况的友友吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eab8634806, createdName=ms6000000954293507, createdTime=Fri May 26 09:07:39 CST 2023, time=2023-05-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2177803, encodeId=19a121e7803be, content=让我修了两轮的格式和图片<br>12.25 submitted to journal<br>12.26 under editor assessment, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20240101/570c45f5d7f2451da2e0a51a7b25b479/824b9aa7cdc24982879c3db6cbeb3798.jpg, createdBy=a3422257516, createdName=samtol, createdTime=Thu Dec 28 15:41:53 CST 2023, time=2023-12-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2161515, encodeId=c19f2161515a5, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:中药抗肿瘤<br>经验分享:一审速度比较快,5月投稿,6月收到修改意见,二审、三审速度就非常慢!7月26号根据一审意见返回杂志社,9月18号返回二审意见,只有修改题目一条意见,19号修回后,26号才发邮件告知修改格式,当天修改完提交后,等到10月4日才显示状态改变,10月5日变成under review,发出2个review invitations,1个accept。。。真是太漫长了,感觉编辑1周处理一次稿件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=63b45479551, createdName=ms5000000155404164, createdTime=Sun Oct 08 11:32:31 CST 2023, time=2023-10-08, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=1237955, encodeId=4429123e9555f, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:中药药理;中药复方<br>经验分享:5.30投稿<br>5.31要求提供缩略词,补充后当晚提交了<br>6.6 under review<br>6.22 Required Reviews Completed<br>6.26 revise<br>主编+6个审稿专家,加起来50多个问题,审稿意见非常细节,很注重创新性。还好整体评价比较积极,对文章大框架没什么意见,只给了我3周修改,我还补了一点实验,最后几天写回复写到怀疑人生……<br>7.14 summit<br>7.15 Under Editor Assessment<br>7.24 under review<br>8.2 Required Reviews Completed<br>8.3 Decision in Process<br>8.4 accepted<br>8.6 Proof<br><br>感谢主编和外审专家们!第一次投sci,好多地方都不清楚,每天都快把论坛翻烂了……还好最后顺利接收,写一点我在翻帖子时大家提问多的事情吧:1.Author Agreement:这个在爱思唯尔投稿作者须知那里有个链接能下载,有点不太好找。2.western结果:revise时要求提供原始未裁剪的膜,这个前期做实验的时候需要注意下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=feb46571516, createdName=msyukira, createdTime=Wed Aug 10 23:59:55 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197546, encodeId=6fd1219e54687, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:中药复方<br>经验分享:想问一下各位已投稿的宝子们phytomedicine复方投稿需要提供指纹图谱吗,没有怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=468e9243712, createdName=ms8000002041881019, createdTime=Tue Apr 09 10:23:45 CST 2024, time=2024-04-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2126674, encodeId=3a3521266e454, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:中药复方;代谢病<br>经验分享:2023.02.25 submit<br>2023.03.03 under editor assessment<br>2023.03.09 under review<br>2023.03.19 required reviews completed<br>2023.03.25 revise,审稿人意见都比较积极,算是小修、润色、降重。给了20天修回。<br>2023.04.12 返回<br>2023.04.17 under editor assessment<br>2023.04.18 reviewer invited<br>目前是这种状态,后续再更新状态。<br><br>希望能够顺利接收,总体来讲,审稿人如果审的快的话一个月就可以完成。<br>编辑和杂志都不错,效率其实还行。<br><br>希望能赶在毕业前接收~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54158562904, createdName=ms2000000770833142, createdTime=Tue Apr 18 09:45:29 CST 2023, time=2023-04-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2131405, encodeId=6236213140557, content=想要询问一下以下情况如何解决:<br><br>(X) Author agreement<br>(has to be uploaded as an extra file; Format: MS Word, TIF, EPS, … (not .pdf please!))<br>The author agreement form for this journal with all author signatures is required. The signature of corresponding author is mandatory.<br>(https://www.elsevier.com/__data/promis_misc/710660_aucc_author_agreement.pdf)<br>(X) Format: Acceptable text file formats include MS Word, Word Perfect, RTF, TEX or plain ASCII text. TIF and EPS files are preferred for figures. PDF, DVI and PS files are not acceptable for publishing purposes.<br>(X) Figure legends. Only text; before figures<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57318663160, createdName=ms1000001447770011, createdTime=Wed May 10 14:57:44 CST 2023, time=2023-05-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2130918, encodeId=df56213091879, content=咨询大家一下,投稿出现这些问题,要如何处理呢?<br><br>(X)Figure legends. Only text; before figures<br><br>(X) Figures separately, also at the end of the manuscript have to be uploaded as an extra file (Format: TIF, EPS) without legends<br><br>(X) Reference list according to our journal style.<br>--&gt; In alphabetical order without numbers<br>--&gt; with ABBREVIATED journal titles.<br>(ex. Goto, N., Ueo, T., Fukuda, A., Kawada, K., Sakai, Y., Miyoshi, H., Taketo, M.M., Chiba, T., Seno, H., 2017. Distinct roles of HES1 in normal stem cells and tumor stem-like cells of the intestine. Cancer Res. 77 (13), 3442-3454.)<br><br>(X) All citations in the text should refer to:<br>1. Single author: the author's name (without initials, unless there is ambiguity) and the year of publication;<br>2. Two authors: both authors' names and the year of publication;<br>3. Three or more authors: first author's name followed by 'et al.' and the year of publication.<br>Citations may be made directly (or parenthetically). Groups of references should be listed first alphabetically, then chronologically.<br>Examples: 'as demonstrated (Allan, 2000a, 2000b, 1999; Allan and Jones, 1999).(Kramer et al.,2010). Kramer et al. (2010) have recently shown .…'<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b168663492, createdName=ms7000000863199411, createdTime=Mon May 08 09:20:15 CST 2023, time=2023-05-08, status=1, ipAttribution=江西省)]
    2023-05-26 ms6000000954293507 来自北京

    审稿速度:3.0 | 投稿命中率:50.0
    偏重的研究方向:肾脏病;中药复方
    经验分享:请问Proof后多久才能出版呢,已经Proof两周了,没有动静,并且Pre-Online是未Proof版本,上周已邮件咨询过,回复是正在校稿,这快两周过去了,有知道情况的友友吗?

    2

    展开2条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2122040, encodeId=eb54212204091, content=审稿速度:12.0 | 投稿命中率:50.0<br>偏重的研究方向:中药<br>经验分享:想请问大家,Under Editor Assessment这个状态卡了快一个月了,是什么意思呀,可以发邮件催一下吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fc65556145, createdName=ms4000000742058182, createdTime=Mon Mar 27 11:02:07 CST 2023, time=2023-03-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2198636, encodeId=1943219863695, content=请问proof返回后大概多久online啊,已经大半个月了还没有online🥹, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c368992874, createdName=ms6000000634273240, createdTime=Mon Apr 15 17:05:20 CST 2024, time=2024-04-15, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2139117, encodeId=8f50213911ec7, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肾脏病;中药复方<br>经验分享:请问Proof后多久才能出版呢,已经Proof两周了,没有动静,并且Pre-Online是未Proof版本,上周已邮件咨询过,回复是正在校稿,这快两周过去了,有知道情况的友友吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eab8634806, createdName=ms6000000954293507, createdTime=Fri May 26 09:07:39 CST 2023, time=2023-05-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2177803, encodeId=19a121e7803be, content=让我修了两轮的格式和图片<br>12.25 submitted to journal<br>12.26 under editor assessment, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20240101/570c45f5d7f2451da2e0a51a7b25b479/824b9aa7cdc24982879c3db6cbeb3798.jpg, createdBy=a3422257516, createdName=samtol, createdTime=Thu Dec 28 15:41:53 CST 2023, time=2023-12-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2161515, encodeId=c19f2161515a5, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:中药抗肿瘤<br>经验分享:一审速度比较快,5月投稿,6月收到修改意见,二审、三审速度就非常慢!7月26号根据一审意见返回杂志社,9月18号返回二审意见,只有修改题目一条意见,19号修回后,26号才发邮件告知修改格式,当天修改完提交后,等到10月4日才显示状态改变,10月5日变成under review,发出2个review invitations,1个accept。。。真是太漫长了,感觉编辑1周处理一次稿件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=63b45479551, createdName=ms5000000155404164, createdTime=Sun Oct 08 11:32:31 CST 2023, time=2023-10-08, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=1237955, encodeId=4429123e9555f, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:中药药理;中药复方<br>经验分享:5.30投稿<br>5.31要求提供缩略词,补充后当晚提交了<br>6.6 under review<br>6.22 Required Reviews Completed<br>6.26 revise<br>主编+6个审稿专家,加起来50多个问题,审稿意见非常细节,很注重创新性。还好整体评价比较积极,对文章大框架没什么意见,只给了我3周修改,我还补了一点实验,最后几天写回复写到怀疑人生……<br>7.14 summit<br>7.15 Under Editor Assessment<br>7.24 under review<br>8.2 Required Reviews Completed<br>8.3 Decision in Process<br>8.4 accepted<br>8.6 Proof<br><br>感谢主编和外审专家们!第一次投sci,好多地方都不清楚,每天都快把论坛翻烂了……还好最后顺利接收,写一点我在翻帖子时大家提问多的事情吧:1.Author Agreement:这个在爱思唯尔投稿作者须知那里有个链接能下载,有点不太好找。2.western结果:revise时要求提供原始未裁剪的膜,这个前期做实验的时候需要注意下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=feb46571516, createdName=msyukira, createdTime=Wed Aug 10 23:59:55 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197546, encodeId=6fd1219e54687, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:中药复方<br>经验分享:想问一下各位已投稿的宝子们phytomedicine复方投稿需要提供指纹图谱吗,没有怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=468e9243712, createdName=ms8000002041881019, createdTime=Tue Apr 09 10:23:45 CST 2024, time=2024-04-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2126674, encodeId=3a3521266e454, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:中药复方;代谢病<br>经验分享:2023.02.25 submit<br>2023.03.03 under editor assessment<br>2023.03.09 under review<br>2023.03.19 required reviews completed<br>2023.03.25 revise,审稿人意见都比较积极,算是小修、润色、降重。给了20天修回。<br>2023.04.12 返回<br>2023.04.17 under editor assessment<br>2023.04.18 reviewer invited<br>目前是这种状态,后续再更新状态。<br><br>希望能够顺利接收,总体来讲,审稿人如果审的快的话一个月就可以完成。<br>编辑和杂志都不错,效率其实还行。<br><br>希望能赶在毕业前接收~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54158562904, createdName=ms2000000770833142, createdTime=Tue Apr 18 09:45:29 CST 2023, time=2023-04-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2131405, encodeId=6236213140557, content=想要询问一下以下情况如何解决:<br><br>(X) Author agreement<br>(has to be uploaded as an extra file; Format: MS Word, TIF, EPS, … (not .pdf please!))<br>The author agreement form for this journal with all author signatures is required. The signature of corresponding author is mandatory.<br>(https://www.elsevier.com/__data/promis_misc/710660_aucc_author_agreement.pdf)<br>(X) Format: Acceptable text file formats include MS Word, Word Perfect, RTF, TEX or plain ASCII text. TIF and EPS files are preferred for figures. PDF, DVI and PS files are not acceptable for publishing purposes.<br>(X) Figure legends. Only text; before figures<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57318663160, createdName=ms1000001447770011, createdTime=Wed May 10 14:57:44 CST 2023, time=2023-05-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2130918, encodeId=df56213091879, content=咨询大家一下,投稿出现这些问题,要如何处理呢?<br><br>(X)Figure legends. Only text; before figures<br><br>(X) Figures separately, also at the end of the manuscript have to be uploaded as an extra file (Format: TIF, EPS) without legends<br><br>(X) Reference list according to our journal style.<br>--&gt; In alphabetical order without numbers<br>--&gt; with ABBREVIATED journal titles.<br>(ex. Goto, N., Ueo, T., Fukuda, A., Kawada, K., Sakai, Y., Miyoshi, H., Taketo, M.M., Chiba, T., Seno, H., 2017. Distinct roles of HES1 in normal stem cells and tumor stem-like cells of the intestine. Cancer Res. 77 (13), 3442-3454.)<br><br>(X) All citations in the text should refer to:<br>1. Single author: the author's name (without initials, unless there is ambiguity) and the year of publication;<br>2. Two authors: both authors' names and the year of publication;<br>3. Three or more authors: first author's name followed by 'et al.' and the year of publication.<br>Citations may be made directly (or parenthetically). Groups of references should be listed first alphabetically, then chronologically.<br>Examples: 'as demonstrated (Allan, 2000a, 2000b, 1999; Allan and Jones, 1999).(Kramer et al.,2010). Kramer et al. (2010) have recently shown .…'<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b168663492, createdName=ms7000000863199411, createdTime=Mon May 08 09:20:15 CST 2023, time=2023-05-08, status=1, ipAttribution=江西省)]
    2023-12-28 samtol 来自浙江省

    让我修了两轮的格式和图片
    12.25 submitted to journal
    12.26 under editor assessment

    24

    展开24条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2122040, encodeId=eb54212204091, content=审稿速度:12.0 | 投稿命中率:50.0<br>偏重的研究方向:中药<br>经验分享:想请问大家,Under Editor Assessment这个状态卡了快一个月了,是什么意思呀,可以发邮件催一下吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fc65556145, createdName=ms4000000742058182, createdTime=Mon Mar 27 11:02:07 CST 2023, time=2023-03-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2198636, encodeId=1943219863695, content=请问proof返回后大概多久online啊,已经大半个月了还没有online🥹, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c368992874, createdName=ms6000000634273240, createdTime=Mon Apr 15 17:05:20 CST 2024, time=2024-04-15, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2139117, encodeId=8f50213911ec7, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肾脏病;中药复方<br>经验分享:请问Proof后多久才能出版呢,已经Proof两周了,没有动静,并且Pre-Online是未Proof版本,上周已邮件咨询过,回复是正在校稿,这快两周过去了,有知道情况的友友吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eab8634806, createdName=ms6000000954293507, createdTime=Fri May 26 09:07:39 CST 2023, time=2023-05-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2177803, encodeId=19a121e7803be, content=让我修了两轮的格式和图片<br>12.25 submitted to journal<br>12.26 under editor assessment, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20240101/570c45f5d7f2451da2e0a51a7b25b479/824b9aa7cdc24982879c3db6cbeb3798.jpg, createdBy=a3422257516, createdName=samtol, createdTime=Thu Dec 28 15:41:53 CST 2023, time=2023-12-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2161515, encodeId=c19f2161515a5, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:中药抗肿瘤<br>经验分享:一审速度比较快,5月投稿,6月收到修改意见,二审、三审速度就非常慢!7月26号根据一审意见返回杂志社,9月18号返回二审意见,只有修改题目一条意见,19号修回后,26号才发邮件告知修改格式,当天修改完提交后,等到10月4日才显示状态改变,10月5日变成under review,发出2个review invitations,1个accept。。。真是太漫长了,感觉编辑1周处理一次稿件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=63b45479551, createdName=ms5000000155404164, createdTime=Sun Oct 08 11:32:31 CST 2023, time=2023-10-08, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=1237955, encodeId=4429123e9555f, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:中药药理;中药复方<br>经验分享:5.30投稿<br>5.31要求提供缩略词,补充后当晚提交了<br>6.6 under review<br>6.22 Required Reviews Completed<br>6.26 revise<br>主编+6个审稿专家,加起来50多个问题,审稿意见非常细节,很注重创新性。还好整体评价比较积极,对文章大框架没什么意见,只给了我3周修改,我还补了一点实验,最后几天写回复写到怀疑人生……<br>7.14 summit<br>7.15 Under Editor Assessment<br>7.24 under review<br>8.2 Required Reviews Completed<br>8.3 Decision in Process<br>8.4 accepted<br>8.6 Proof<br><br>感谢主编和外审专家们!第一次投sci,好多地方都不清楚,每天都快把论坛翻烂了……还好最后顺利接收,写一点我在翻帖子时大家提问多的事情吧:1.Author Agreement:这个在爱思唯尔投稿作者须知那里有个链接能下载,有点不太好找。2.western结果:revise时要求提供原始未裁剪的膜,这个前期做实验的时候需要注意下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=feb46571516, createdName=msyukira, createdTime=Wed Aug 10 23:59:55 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197546, encodeId=6fd1219e54687, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:中药复方<br>经验分享:想问一下各位已投稿的宝子们phytomedicine复方投稿需要提供指纹图谱吗,没有怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=468e9243712, createdName=ms8000002041881019, createdTime=Tue Apr 09 10:23:45 CST 2024, time=2024-04-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2126674, encodeId=3a3521266e454, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:中药复方;代谢病<br>经验分享:2023.02.25 submit<br>2023.03.03 under editor assessment<br>2023.03.09 under review<br>2023.03.19 required reviews completed<br>2023.03.25 revise,审稿人意见都比较积极,算是小修、润色、降重。给了20天修回。<br>2023.04.12 返回<br>2023.04.17 under editor assessment<br>2023.04.18 reviewer invited<br>目前是这种状态,后续再更新状态。<br><br>希望能够顺利接收,总体来讲,审稿人如果审的快的话一个月就可以完成。<br>编辑和杂志都不错,效率其实还行。<br><br>希望能赶在毕业前接收~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54158562904, createdName=ms2000000770833142, createdTime=Tue Apr 18 09:45:29 CST 2023, time=2023-04-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2131405, encodeId=6236213140557, content=想要询问一下以下情况如何解决:<br><br>(X) Author agreement<br>(has to be uploaded as an extra file; Format: MS Word, TIF, EPS, … (not .pdf please!))<br>The author agreement form for this journal with all author signatures is required. The signature of corresponding author is mandatory.<br>(https://www.elsevier.com/__data/promis_misc/710660_aucc_author_agreement.pdf)<br>(X) Format: Acceptable text file formats include MS Word, Word Perfect, RTF, TEX or plain ASCII text. TIF and EPS files are preferred for figures. PDF, DVI and PS files are not acceptable for publishing purposes.<br>(X) Figure legends. Only text; before figures<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57318663160, createdName=ms1000001447770011, createdTime=Wed May 10 14:57:44 CST 2023, time=2023-05-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2130918, encodeId=df56213091879, content=咨询大家一下,投稿出现这些问题,要如何处理呢?<br><br>(X)Figure legends. Only text; before figures<br><br>(X) Figures separately, also at the end of the manuscript have to be uploaded as an extra file (Format: TIF, EPS) without legends<br><br>(X) Reference list according to our journal style.<br>--&gt; In alphabetical order without numbers<br>--&gt; with ABBREVIATED journal titles.<br>(ex. Goto, N., Ueo, T., Fukuda, A., Kawada, K., Sakai, Y., Miyoshi, H., Taketo, M.M., Chiba, T., Seno, H., 2017. Distinct roles of HES1 in normal stem cells and tumor stem-like cells of the intestine. Cancer Res. 77 (13), 3442-3454.)<br><br>(X) All citations in the text should refer to:<br>1. Single author: the author's name (without initials, unless there is ambiguity) and the year of publication;<br>2. Two authors: both authors' names and the year of publication;<br>3. Three or more authors: first author's name followed by 'et al.' and the year of publication.<br>Citations may be made directly (or parenthetically). Groups of references should be listed first alphabetically, then chronologically.<br>Examples: 'as demonstrated (Allan, 2000a, 2000b, 1999; Allan and Jones, 1999).(Kramer et al.,2010). Kramer et al. (2010) have recently shown .…'<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b168663492, createdName=ms7000000863199411, createdTime=Mon May 08 09:20:15 CST 2023, time=2023-05-08, status=1, ipAttribution=江西省)]
    2023-10-08 ms5000000155404164 来自吉林省

    审稿速度:6.0 | 投稿命中率:50.0
    偏重的研究方向:中药抗肿瘤
    经验分享:一审速度比较快,5月投稿,6月收到修改意见,二审、三审速度就非常慢!7月26号根据一审意见返回杂志社,9月18号返回二审意见,只有修改题目一条意见,19号修回后,26号才发邮件告知修改格式,当天修改完提交后,等到10月4日才显示状态改变,10月5日变成under review,发出2个review invitations,1个accept。。。真是太漫长了,感觉编辑1周处理一次稿件

    5

    展开5条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2122040, encodeId=eb54212204091, content=审稿速度:12.0 | 投稿命中率:50.0<br>偏重的研究方向:中药<br>经验分享:想请问大家,Under Editor Assessment这个状态卡了快一个月了,是什么意思呀,可以发邮件催一下吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fc65556145, createdName=ms4000000742058182, createdTime=Mon Mar 27 11:02:07 CST 2023, time=2023-03-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2198636, encodeId=1943219863695, content=请问proof返回后大概多久online啊,已经大半个月了还没有online🥹, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c368992874, createdName=ms6000000634273240, createdTime=Mon Apr 15 17:05:20 CST 2024, time=2024-04-15, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2139117, encodeId=8f50213911ec7, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肾脏病;中药复方<br>经验分享:请问Proof后多久才能出版呢,已经Proof两周了,没有动静,并且Pre-Online是未Proof版本,上周已邮件咨询过,回复是正在校稿,这快两周过去了,有知道情况的友友吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eab8634806, createdName=ms6000000954293507, createdTime=Fri May 26 09:07:39 CST 2023, time=2023-05-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2177803, encodeId=19a121e7803be, content=让我修了两轮的格式和图片<br>12.25 submitted to journal<br>12.26 under editor assessment, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20240101/570c45f5d7f2451da2e0a51a7b25b479/824b9aa7cdc24982879c3db6cbeb3798.jpg, createdBy=a3422257516, createdName=samtol, createdTime=Thu Dec 28 15:41:53 CST 2023, time=2023-12-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2161515, encodeId=c19f2161515a5, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:中药抗肿瘤<br>经验分享:一审速度比较快,5月投稿,6月收到修改意见,二审、三审速度就非常慢!7月26号根据一审意见返回杂志社,9月18号返回二审意见,只有修改题目一条意见,19号修回后,26号才发邮件告知修改格式,当天修改完提交后,等到10月4日才显示状态改变,10月5日变成under review,发出2个review invitations,1个accept。。。真是太漫长了,感觉编辑1周处理一次稿件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=63b45479551, createdName=ms5000000155404164, createdTime=Sun Oct 08 11:32:31 CST 2023, time=2023-10-08, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=1237955, encodeId=4429123e9555f, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:中药药理;中药复方<br>经验分享:5.30投稿<br>5.31要求提供缩略词,补充后当晚提交了<br>6.6 under review<br>6.22 Required Reviews Completed<br>6.26 revise<br>主编+6个审稿专家,加起来50多个问题,审稿意见非常细节,很注重创新性。还好整体评价比较积极,对文章大框架没什么意见,只给了我3周修改,我还补了一点实验,最后几天写回复写到怀疑人生……<br>7.14 summit<br>7.15 Under Editor Assessment<br>7.24 under review<br>8.2 Required Reviews Completed<br>8.3 Decision in Process<br>8.4 accepted<br>8.6 Proof<br><br>感谢主编和外审专家们!第一次投sci,好多地方都不清楚,每天都快把论坛翻烂了……还好最后顺利接收,写一点我在翻帖子时大家提问多的事情吧:1.Author Agreement:这个在爱思唯尔投稿作者须知那里有个链接能下载,有点不太好找。2.western结果:revise时要求提供原始未裁剪的膜,这个前期做实验的时候需要注意下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=feb46571516, createdName=msyukira, createdTime=Wed Aug 10 23:59:55 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197546, encodeId=6fd1219e54687, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:中药复方<br>经验分享:想问一下各位已投稿的宝子们phytomedicine复方投稿需要提供指纹图谱吗,没有怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=468e9243712, createdName=ms8000002041881019, createdTime=Tue Apr 09 10:23:45 CST 2024, time=2024-04-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2126674, encodeId=3a3521266e454, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:中药复方;代谢病<br>经验分享:2023.02.25 submit<br>2023.03.03 under editor assessment<br>2023.03.09 under review<br>2023.03.19 required reviews completed<br>2023.03.25 revise,审稿人意见都比较积极,算是小修、润色、降重。给了20天修回。<br>2023.04.12 返回<br>2023.04.17 under editor assessment<br>2023.04.18 reviewer invited<br>目前是这种状态,后续再更新状态。<br><br>希望能够顺利接收,总体来讲,审稿人如果审的快的话一个月就可以完成。<br>编辑和杂志都不错,效率其实还行。<br><br>希望能赶在毕业前接收~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54158562904, createdName=ms2000000770833142, createdTime=Tue Apr 18 09:45:29 CST 2023, time=2023-04-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2131405, encodeId=6236213140557, content=想要询问一下以下情况如何解决:<br><br>(X) Author agreement<br>(has to be uploaded as an extra file; Format: MS Word, TIF, EPS, … (not .pdf please!))<br>The author agreement form for this journal with all author signatures is required. The signature of corresponding author is mandatory.<br>(https://www.elsevier.com/__data/promis_misc/710660_aucc_author_agreement.pdf)<br>(X) Format: Acceptable text file formats include MS Word, Word Perfect, RTF, TEX or plain ASCII text. TIF and EPS files are preferred for figures. PDF, DVI and PS files are not acceptable for publishing purposes.<br>(X) Figure legends. Only text; before figures<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57318663160, createdName=ms1000001447770011, createdTime=Wed May 10 14:57:44 CST 2023, time=2023-05-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2130918, encodeId=df56213091879, content=咨询大家一下,投稿出现这些问题,要如何处理呢?<br><br>(X)Figure legends. Only text; before figures<br><br>(X) Figures separately, also at the end of the manuscript have to be uploaded as an extra file (Format: TIF, EPS) without legends<br><br>(X) Reference list according to our journal style.<br>--&gt; In alphabetical order without numbers<br>--&gt; with ABBREVIATED journal titles.<br>(ex. Goto, N., Ueo, T., Fukuda, A., Kawada, K., Sakai, Y., Miyoshi, H., Taketo, M.M., Chiba, T., Seno, H., 2017. Distinct roles of HES1 in normal stem cells and tumor stem-like cells of the intestine. Cancer Res. 77 (13), 3442-3454.)<br><br>(X) All citations in the text should refer to:<br>1. Single author: the author's name (without initials, unless there is ambiguity) and the year of publication;<br>2. Two authors: both authors' names and the year of publication;<br>3. Three or more authors: first author's name followed by 'et al.' and the year of publication.<br>Citations may be made directly (or parenthetically). Groups of references should be listed first alphabetically, then chronologically.<br>Examples: 'as demonstrated (Allan, 2000a, 2000b, 1999; Allan and Jones, 1999).(Kramer et al.,2010). Kramer et al. (2010) have recently shown .…'<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b168663492, createdName=ms7000000863199411, createdTime=Mon May 08 09:20:15 CST 2023, time=2023-05-08, status=1, ipAttribution=江西省)]
    2022-08-10 msyukira

    审稿速度:3.0 | 投稿命中率:50.0
    偏重的研究方向:中药药理;中药复方
    经验分享:5.30投稿
    5.31要求提供缩略词,补充后当晚提交了
    6.6 under review
    6.22 Required Reviews Completed
    6.26 revise
    主编+6个审稿专家,加起来50多个问题,审稿意见非常细节,很注重创新性。还好整体评价比较积极,对文章大框架没什么意见,只给了我3周修改,我还补了一点实验,最后几天写回复写到怀疑人生……
    7.14 summit
    7.15 Under Editor Assessment
    7.24 under review
    8.2 Required Reviews Completed
    8.3 Decision in Process
    8.4 accepted
    8.6 Proof

    感谢主编和外审专家们!第一次投sci,好多地方都不清楚,每天都快把论坛翻烂了……还好最后顺利接收,写一点我在翻帖子时大家提问多的事情吧:1.Author Agreement:这个在爱思唯尔投稿作者须知那里有个链接能下载,有点不太好找。2.western结果:revise时要求提供原始未裁剪的膜,这个前期做实验的时候需要注意下

    6

    展开6条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2122040, encodeId=eb54212204091, content=审稿速度:12.0 | 投稿命中率:50.0<br>偏重的研究方向:中药<br>经验分享:想请问大家,Under Editor Assessment这个状态卡了快一个月了,是什么意思呀,可以发邮件催一下吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fc65556145, createdName=ms4000000742058182, createdTime=Mon Mar 27 11:02:07 CST 2023, time=2023-03-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2198636, encodeId=1943219863695, content=请问proof返回后大概多久online啊,已经大半个月了还没有online🥹, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c368992874, createdName=ms6000000634273240, createdTime=Mon Apr 15 17:05:20 CST 2024, time=2024-04-15, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2139117, encodeId=8f50213911ec7, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肾脏病;中药复方<br>经验分享:请问Proof后多久才能出版呢,已经Proof两周了,没有动静,并且Pre-Online是未Proof版本,上周已邮件咨询过,回复是正在校稿,这快两周过去了,有知道情况的友友吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eab8634806, createdName=ms6000000954293507, createdTime=Fri May 26 09:07:39 CST 2023, time=2023-05-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2177803, encodeId=19a121e7803be, content=让我修了两轮的格式和图片<br>12.25 submitted to journal<br>12.26 under editor assessment, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20240101/570c45f5d7f2451da2e0a51a7b25b479/824b9aa7cdc24982879c3db6cbeb3798.jpg, createdBy=a3422257516, createdName=samtol, createdTime=Thu Dec 28 15:41:53 CST 2023, time=2023-12-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2161515, encodeId=c19f2161515a5, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:中药抗肿瘤<br>经验分享:一审速度比较快,5月投稿,6月收到修改意见,二审、三审速度就非常慢!7月26号根据一审意见返回杂志社,9月18号返回二审意见,只有修改题目一条意见,19号修回后,26号才发邮件告知修改格式,当天修改完提交后,等到10月4日才显示状态改变,10月5日变成under review,发出2个review invitations,1个accept。。。真是太漫长了,感觉编辑1周处理一次稿件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=63b45479551, createdName=ms5000000155404164, createdTime=Sun Oct 08 11:32:31 CST 2023, time=2023-10-08, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=1237955, encodeId=4429123e9555f, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:中药药理;中药复方<br>经验分享:5.30投稿<br>5.31要求提供缩略词,补充后当晚提交了<br>6.6 under review<br>6.22 Required Reviews Completed<br>6.26 revise<br>主编+6个审稿专家,加起来50多个问题,审稿意见非常细节,很注重创新性。还好整体评价比较积极,对文章大框架没什么意见,只给了我3周修改,我还补了一点实验,最后几天写回复写到怀疑人生……<br>7.14 summit<br>7.15 Under Editor Assessment<br>7.24 under review<br>8.2 Required Reviews Completed<br>8.3 Decision in Process<br>8.4 accepted<br>8.6 Proof<br><br>感谢主编和外审专家们!第一次投sci,好多地方都不清楚,每天都快把论坛翻烂了……还好最后顺利接收,写一点我在翻帖子时大家提问多的事情吧:1.Author Agreement:这个在爱思唯尔投稿作者须知那里有个链接能下载,有点不太好找。2.western结果:revise时要求提供原始未裁剪的膜,这个前期做实验的时候需要注意下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=feb46571516, createdName=msyukira, createdTime=Wed Aug 10 23:59:55 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197546, encodeId=6fd1219e54687, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:中药复方<br>经验分享:想问一下各位已投稿的宝子们phytomedicine复方投稿需要提供指纹图谱吗,没有怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=468e9243712, createdName=ms8000002041881019, createdTime=Tue Apr 09 10:23:45 CST 2024, time=2024-04-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2126674, encodeId=3a3521266e454, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:中药复方;代谢病<br>经验分享:2023.02.25 submit<br>2023.03.03 under editor assessment<br>2023.03.09 under review<br>2023.03.19 required reviews completed<br>2023.03.25 revise,审稿人意见都比较积极,算是小修、润色、降重。给了20天修回。<br>2023.04.12 返回<br>2023.04.17 under editor assessment<br>2023.04.18 reviewer invited<br>目前是这种状态,后续再更新状态。<br><br>希望能够顺利接收,总体来讲,审稿人如果审的快的话一个月就可以完成。<br>编辑和杂志都不错,效率其实还行。<br><br>希望能赶在毕业前接收~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54158562904, createdName=ms2000000770833142, createdTime=Tue Apr 18 09:45:29 CST 2023, time=2023-04-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2131405, encodeId=6236213140557, content=想要询问一下以下情况如何解决:<br><br>(X) Author agreement<br>(has to be uploaded as an extra file; Format: MS Word, TIF, EPS, … (not .pdf please!))<br>The author agreement form for this journal with all author signatures is required. The signature of corresponding author is mandatory.<br>(https://www.elsevier.com/__data/promis_misc/710660_aucc_author_agreement.pdf)<br>(X) Format: Acceptable text file formats include MS Word, Word Perfect, RTF, TEX or plain ASCII text. TIF and EPS files are preferred for figures. PDF, DVI and PS files are not acceptable for publishing purposes.<br>(X) Figure legends. Only text; before figures<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57318663160, createdName=ms1000001447770011, createdTime=Wed May 10 14:57:44 CST 2023, time=2023-05-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2130918, encodeId=df56213091879, content=咨询大家一下,投稿出现这些问题,要如何处理呢?<br><br>(X)Figure legends. Only text; before figures<br><br>(X) Figures separately, also at the end of the manuscript have to be uploaded as an extra file (Format: TIF, EPS) without legends<br><br>(X) Reference list according to our journal style.<br>--&gt; In alphabetical order without numbers<br>--&gt; with ABBREVIATED journal titles.<br>(ex. Goto, N., Ueo, T., Fukuda, A., Kawada, K., Sakai, Y., Miyoshi, H., Taketo, M.M., Chiba, T., Seno, H., 2017. Distinct roles of HES1 in normal stem cells and tumor stem-like cells of the intestine. Cancer Res. 77 (13), 3442-3454.)<br><br>(X) All citations in the text should refer to:<br>1. Single author: the author's name (without initials, unless there is ambiguity) and the year of publication;<br>2. Two authors: both authors' names and the year of publication;<br>3. Three or more authors: first author's name followed by 'et al.' and the year of publication.<br>Citations may be made directly (or parenthetically). Groups of references should be listed first alphabetically, then chronologically.<br>Examples: 'as demonstrated (Allan, 2000a, 2000b, 1999; Allan and Jones, 1999).(Kramer et al.,2010). Kramer et al. (2010) have recently shown .…'<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b168663492, createdName=ms7000000863199411, createdTime=Mon May 08 09:20:15 CST 2023, time=2023-05-08, status=1, ipAttribution=江西省)]
    2024-04-09 ms8000002041881019 来自北京

    审稿速度:3.0 | 投稿命中率:50.0
    偏重的研究方向:中药复方
    经验分享:想问一下各位已投稿的宝子们phytomedicine复方投稿需要提供指纹图谱吗,没有怎么办

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2122040, encodeId=eb54212204091, content=审稿速度:12.0 | 投稿命中率:50.0<br>偏重的研究方向:中药<br>经验分享:想请问大家,Under Editor Assessment这个状态卡了快一个月了,是什么意思呀,可以发邮件催一下吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fc65556145, createdName=ms4000000742058182, createdTime=Mon Mar 27 11:02:07 CST 2023, time=2023-03-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2198636, encodeId=1943219863695, content=请问proof返回后大概多久online啊,已经大半个月了还没有online🥹, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c368992874, createdName=ms6000000634273240, createdTime=Mon Apr 15 17:05:20 CST 2024, time=2024-04-15, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2139117, encodeId=8f50213911ec7, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肾脏病;中药复方<br>经验分享:请问Proof后多久才能出版呢,已经Proof两周了,没有动静,并且Pre-Online是未Proof版本,上周已邮件咨询过,回复是正在校稿,这快两周过去了,有知道情况的友友吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eab8634806, createdName=ms6000000954293507, createdTime=Fri May 26 09:07:39 CST 2023, time=2023-05-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2177803, encodeId=19a121e7803be, content=让我修了两轮的格式和图片<br>12.25 submitted to journal<br>12.26 under editor assessment, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20240101/570c45f5d7f2451da2e0a51a7b25b479/824b9aa7cdc24982879c3db6cbeb3798.jpg, createdBy=a3422257516, createdName=samtol, createdTime=Thu Dec 28 15:41:53 CST 2023, time=2023-12-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2161515, encodeId=c19f2161515a5, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:中药抗肿瘤<br>经验分享:一审速度比较快,5月投稿,6月收到修改意见,二审、三审速度就非常慢!7月26号根据一审意见返回杂志社,9月18号返回二审意见,只有修改题目一条意见,19号修回后,26号才发邮件告知修改格式,当天修改完提交后,等到10月4日才显示状态改变,10月5日变成under review,发出2个review invitations,1个accept。。。真是太漫长了,感觉编辑1周处理一次稿件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=63b45479551, createdName=ms5000000155404164, createdTime=Sun Oct 08 11:32:31 CST 2023, time=2023-10-08, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=1237955, encodeId=4429123e9555f, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:中药药理;中药复方<br>经验分享:5.30投稿<br>5.31要求提供缩略词,补充后当晚提交了<br>6.6 under review<br>6.22 Required Reviews Completed<br>6.26 revise<br>主编+6个审稿专家,加起来50多个问题,审稿意见非常细节,很注重创新性。还好整体评价比较积极,对文章大框架没什么意见,只给了我3周修改,我还补了一点实验,最后几天写回复写到怀疑人生……<br>7.14 summit<br>7.15 Under Editor Assessment<br>7.24 under review<br>8.2 Required Reviews Completed<br>8.3 Decision in Process<br>8.4 accepted<br>8.6 Proof<br><br>感谢主编和外审专家们!第一次投sci,好多地方都不清楚,每天都快把论坛翻烂了……还好最后顺利接收,写一点我在翻帖子时大家提问多的事情吧:1.Author Agreement:这个在爱思唯尔投稿作者须知那里有个链接能下载,有点不太好找。2.western结果:revise时要求提供原始未裁剪的膜,这个前期做实验的时候需要注意下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=feb46571516, createdName=msyukira, createdTime=Wed Aug 10 23:59:55 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197546, encodeId=6fd1219e54687, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:中药复方<br>经验分享:想问一下各位已投稿的宝子们phytomedicine复方投稿需要提供指纹图谱吗,没有怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=468e9243712, createdName=ms8000002041881019, createdTime=Tue Apr 09 10:23:45 CST 2024, time=2024-04-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2126674, encodeId=3a3521266e454, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:中药复方;代谢病<br>经验分享:2023.02.25 submit<br>2023.03.03 under editor assessment<br>2023.03.09 under review<br>2023.03.19 required reviews completed<br>2023.03.25 revise,审稿人意见都比较积极,算是小修、润色、降重。给了20天修回。<br>2023.04.12 返回<br>2023.04.17 under editor assessment<br>2023.04.18 reviewer invited<br>目前是这种状态,后续再更新状态。<br><br>希望能够顺利接收,总体来讲,审稿人如果审的快的话一个月就可以完成。<br>编辑和杂志都不错,效率其实还行。<br><br>希望能赶在毕业前接收~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54158562904, createdName=ms2000000770833142, createdTime=Tue Apr 18 09:45:29 CST 2023, time=2023-04-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2131405, encodeId=6236213140557, content=想要询问一下以下情况如何解决:<br><br>(X) Author agreement<br>(has to be uploaded as an extra file; Format: MS Word, TIF, EPS, … (not .pdf please!))<br>The author agreement form for this journal with all author signatures is required. The signature of corresponding author is mandatory.<br>(https://www.elsevier.com/__data/promis_misc/710660_aucc_author_agreement.pdf)<br>(X) Format: Acceptable text file formats include MS Word, Word Perfect, RTF, TEX or plain ASCII text. TIF and EPS files are preferred for figures. PDF, DVI and PS files are not acceptable for publishing purposes.<br>(X) Figure legends. Only text; before figures<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57318663160, createdName=ms1000001447770011, createdTime=Wed May 10 14:57:44 CST 2023, time=2023-05-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2130918, encodeId=df56213091879, content=咨询大家一下,投稿出现这些问题,要如何处理呢?<br><br>(X)Figure legends. Only text; before figures<br><br>(X) Figures separately, also at the end of the manuscript have to be uploaded as an extra file (Format: TIF, EPS) without legends<br><br>(X) Reference list according to our journal style.<br>--&gt; In alphabetical order without numbers<br>--&gt; with ABBREVIATED journal titles.<br>(ex. Goto, N., Ueo, T., Fukuda, A., Kawada, K., Sakai, Y., Miyoshi, H., Taketo, M.M., Chiba, T., Seno, H., 2017. Distinct roles of HES1 in normal stem cells and tumor stem-like cells of the intestine. Cancer Res. 77 (13), 3442-3454.)<br><br>(X) All citations in the text should refer to:<br>1. Single author: the author's name (without initials, unless there is ambiguity) and the year of publication;<br>2. Two authors: both authors' names and the year of publication;<br>3. Three or more authors: first author's name followed by 'et al.' and the year of publication.<br>Citations may be made directly (or parenthetically). Groups of references should be listed first alphabetically, then chronologically.<br>Examples: 'as demonstrated (Allan, 2000a, 2000b, 1999; Allan and Jones, 1999).(Kramer et al.,2010). Kramer et al. (2010) have recently shown .…'<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b168663492, createdName=ms7000000863199411, createdTime=Mon May 08 09:20:15 CST 2023, time=2023-05-08, status=1, ipAttribution=江西省)]
    2023-04-18 ms2000000770833142 来自广东省

    审稿速度:6.0 | 投稿命中率:50.0
    偏重的研究方向:中药复方;代谢病
    经验分享:2023.02.25 submit
    2023.03.03 under editor assessment
    2023.03.09 under review
    2023.03.19 required reviews completed
    2023.03.25 revise,审稿人意见都比较积极,算是小修、润色、降重。给了20天修回。
    2023.04.12 返回
    2023.04.17 under editor assessment
    2023.04.18 reviewer invited
    目前是这种状态,后续再更新状态。

    希望能够顺利接收,总体来讲,审稿人如果审的快的话一个月就可以完成。
    编辑和杂志都不错,效率其实还行。

    希望能赶在毕业前接收~

    20

    展开20条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2122040, encodeId=eb54212204091, content=审稿速度:12.0 | 投稿命中率:50.0<br>偏重的研究方向:中药<br>经验分享:想请问大家,Under Editor Assessment这个状态卡了快一个月了,是什么意思呀,可以发邮件催一下吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fc65556145, createdName=ms4000000742058182, createdTime=Mon Mar 27 11:02:07 CST 2023, time=2023-03-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2198636, encodeId=1943219863695, content=请问proof返回后大概多久online啊,已经大半个月了还没有online🥹, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c368992874, createdName=ms6000000634273240, createdTime=Mon Apr 15 17:05:20 CST 2024, time=2024-04-15, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2139117, encodeId=8f50213911ec7, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肾脏病;中药复方<br>经验分享:请问Proof后多久才能出版呢,已经Proof两周了,没有动静,并且Pre-Online是未Proof版本,上周已邮件咨询过,回复是正在校稿,这快两周过去了,有知道情况的友友吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eab8634806, createdName=ms6000000954293507, createdTime=Fri May 26 09:07:39 CST 2023, time=2023-05-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2177803, encodeId=19a121e7803be, content=让我修了两轮的格式和图片<br>12.25 submitted to journal<br>12.26 under editor assessment, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20240101/570c45f5d7f2451da2e0a51a7b25b479/824b9aa7cdc24982879c3db6cbeb3798.jpg, createdBy=a3422257516, createdName=samtol, createdTime=Thu Dec 28 15:41:53 CST 2023, time=2023-12-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2161515, encodeId=c19f2161515a5, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:中药抗肿瘤<br>经验分享:一审速度比较快,5月投稿,6月收到修改意见,二审、三审速度就非常慢!7月26号根据一审意见返回杂志社,9月18号返回二审意见,只有修改题目一条意见,19号修回后,26号才发邮件告知修改格式,当天修改完提交后,等到10月4日才显示状态改变,10月5日变成under review,发出2个review invitations,1个accept。。。真是太漫长了,感觉编辑1周处理一次稿件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=63b45479551, createdName=ms5000000155404164, createdTime=Sun Oct 08 11:32:31 CST 2023, time=2023-10-08, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=1237955, encodeId=4429123e9555f, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:中药药理;中药复方<br>经验分享:5.30投稿<br>5.31要求提供缩略词,补充后当晚提交了<br>6.6 under review<br>6.22 Required Reviews Completed<br>6.26 revise<br>主编+6个审稿专家,加起来50多个问题,审稿意见非常细节,很注重创新性。还好整体评价比较积极,对文章大框架没什么意见,只给了我3周修改,我还补了一点实验,最后几天写回复写到怀疑人生……<br>7.14 summit<br>7.15 Under Editor Assessment<br>7.24 under review<br>8.2 Required Reviews Completed<br>8.3 Decision in Process<br>8.4 accepted<br>8.6 Proof<br><br>感谢主编和外审专家们!第一次投sci,好多地方都不清楚,每天都快把论坛翻烂了……还好最后顺利接收,写一点我在翻帖子时大家提问多的事情吧:1.Author Agreement:这个在爱思唯尔投稿作者须知那里有个链接能下载,有点不太好找。2.western结果:revise时要求提供原始未裁剪的膜,这个前期做实验的时候需要注意下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=feb46571516, createdName=msyukira, createdTime=Wed Aug 10 23:59:55 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197546, encodeId=6fd1219e54687, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:中药复方<br>经验分享:想问一下各位已投稿的宝子们phytomedicine复方投稿需要提供指纹图谱吗,没有怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=468e9243712, createdName=ms8000002041881019, createdTime=Tue Apr 09 10:23:45 CST 2024, time=2024-04-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2126674, encodeId=3a3521266e454, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:中药复方;代谢病<br>经验分享:2023.02.25 submit<br>2023.03.03 under editor assessment<br>2023.03.09 under review<br>2023.03.19 required reviews completed<br>2023.03.25 revise,审稿人意见都比较积极,算是小修、润色、降重。给了20天修回。<br>2023.04.12 返回<br>2023.04.17 under editor assessment<br>2023.04.18 reviewer invited<br>目前是这种状态,后续再更新状态。<br><br>希望能够顺利接收,总体来讲,审稿人如果审的快的话一个月就可以完成。<br>编辑和杂志都不错,效率其实还行。<br><br>希望能赶在毕业前接收~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54158562904, createdName=ms2000000770833142, createdTime=Tue Apr 18 09:45:29 CST 2023, time=2023-04-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2131405, encodeId=6236213140557, content=想要询问一下以下情况如何解决:<br><br>(X) Author agreement<br>(has to be uploaded as an extra file; Format: MS Word, TIF, EPS, … (not .pdf please!))<br>The author agreement form for this journal with all author signatures is required. The signature of corresponding author is mandatory.<br>(https://www.elsevier.com/__data/promis_misc/710660_aucc_author_agreement.pdf)<br>(X) Format: Acceptable text file formats include MS Word, Word Perfect, RTF, TEX or plain ASCII text. TIF and EPS files are preferred for figures. PDF, DVI and PS files are not acceptable for publishing purposes.<br>(X) Figure legends. Only text; before figures<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57318663160, createdName=ms1000001447770011, createdTime=Wed May 10 14:57:44 CST 2023, time=2023-05-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2130918, encodeId=df56213091879, content=咨询大家一下,投稿出现这些问题,要如何处理呢?<br><br>(X)Figure legends. Only text; before figures<br><br>(X) Figures separately, also at the end of the manuscript have to be uploaded as an extra file (Format: TIF, EPS) without legends<br><br>(X) Reference list according to our journal style.<br>--&gt; In alphabetical order without numbers<br>--&gt; with ABBREVIATED journal titles.<br>(ex. Goto, N., Ueo, T., Fukuda, A., Kawada, K., Sakai, Y., Miyoshi, H., Taketo, M.M., Chiba, T., Seno, H., 2017. Distinct roles of HES1 in normal stem cells and tumor stem-like cells of the intestine. Cancer Res. 77 (13), 3442-3454.)<br><br>(X) All citations in the text should refer to:<br>1. Single author: the author's name (without initials, unless there is ambiguity) and the year of publication;<br>2. Two authors: both authors' names and the year of publication;<br>3. Three or more authors: first author's name followed by 'et al.' and the year of publication.<br>Citations may be made directly (or parenthetically). Groups of references should be listed first alphabetically, then chronologically.<br>Examples: 'as demonstrated (Allan, 2000a, 2000b, 1999; Allan and Jones, 1999).(Kramer et al.,2010). Kramer et al. (2010) have recently shown .…'<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b168663492, createdName=ms7000000863199411, createdTime=Mon May 08 09:20:15 CST 2023, time=2023-05-08, status=1, ipAttribution=江西省)]
    2023-05-10 ms1000001447770011 来自浙江省

    想要询问一下以下情况如何解决:

    (X) Author agreement
    (has to be uploaded as an extra file; Format: MS Word, TIF, EPS, … (not .pdf please!))
    The author agreement form for this journal with all author signatures is required. The signature of corresponding author is mandatory.
    (https://www.elsevier.com/__data/promis_misc/710660_aucc_author_agreement.pdf)
    (X) Format: Acceptable text file formats include MS Word, Word Perfect, RTF, TEX or plain ASCII text. TIF and EPS files are preferred for figures. PDF, DVI and PS files are not acceptable for publishing purposes.
    (X) Figure legends. Only text; before figures

    10

    展开10条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2122040, encodeId=eb54212204091, content=审稿速度:12.0 | 投稿命中率:50.0<br>偏重的研究方向:中药<br>经验分享:想请问大家,Under Editor Assessment这个状态卡了快一个月了,是什么意思呀,可以发邮件催一下吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fc65556145, createdName=ms4000000742058182, createdTime=Mon Mar 27 11:02:07 CST 2023, time=2023-03-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2198636, encodeId=1943219863695, content=请问proof返回后大概多久online啊,已经大半个月了还没有online🥹, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c368992874, createdName=ms6000000634273240, createdTime=Mon Apr 15 17:05:20 CST 2024, time=2024-04-15, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2139117, encodeId=8f50213911ec7, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肾脏病;中药复方<br>经验分享:请问Proof后多久才能出版呢,已经Proof两周了,没有动静,并且Pre-Online是未Proof版本,上周已邮件咨询过,回复是正在校稿,这快两周过去了,有知道情况的友友吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eab8634806, createdName=ms6000000954293507, createdTime=Fri May 26 09:07:39 CST 2023, time=2023-05-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2177803, encodeId=19a121e7803be, content=让我修了两轮的格式和图片<br>12.25 submitted to journal<br>12.26 under editor assessment, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20240101/570c45f5d7f2451da2e0a51a7b25b479/824b9aa7cdc24982879c3db6cbeb3798.jpg, createdBy=a3422257516, createdName=samtol, createdTime=Thu Dec 28 15:41:53 CST 2023, time=2023-12-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2161515, encodeId=c19f2161515a5, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:中药抗肿瘤<br>经验分享:一审速度比较快,5月投稿,6月收到修改意见,二审、三审速度就非常慢!7月26号根据一审意见返回杂志社,9月18号返回二审意见,只有修改题目一条意见,19号修回后,26号才发邮件告知修改格式,当天修改完提交后,等到10月4日才显示状态改变,10月5日变成under review,发出2个review invitations,1个accept。。。真是太漫长了,感觉编辑1周处理一次稿件, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=63b45479551, createdName=ms5000000155404164, createdTime=Sun Oct 08 11:32:31 CST 2023, time=2023-10-08, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=1237955, encodeId=4429123e9555f, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:中药药理;中药复方<br>经验分享:5.30投稿<br>5.31要求提供缩略词,补充后当晚提交了<br>6.6 under review<br>6.22 Required Reviews Completed<br>6.26 revise<br>主编+6个审稿专家,加起来50多个问题,审稿意见非常细节,很注重创新性。还好整体评价比较积极,对文章大框架没什么意见,只给了我3周修改,我还补了一点实验,最后几天写回复写到怀疑人生……<br>7.14 summit<br>7.15 Under Editor Assessment<br>7.24 under review<br>8.2 Required Reviews Completed<br>8.3 Decision in Process<br>8.4 accepted<br>8.6 Proof<br><br>感谢主编和外审专家们!第一次投sci,好多地方都不清楚,每天都快把论坛翻烂了……还好最后顺利接收,写一点我在翻帖子时大家提问多的事情吧:1.Author Agreement:这个在爱思唯尔投稿作者须知那里有个链接能下载,有点不太好找。2.western结果:revise时要求提供原始未裁剪的膜,这个前期做实验的时候需要注意下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=feb46571516, createdName=msyukira, createdTime=Wed Aug 10 23:59:55 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197546, encodeId=6fd1219e54687, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:中药复方<br>经验分享:想问一下各位已投稿的宝子们phytomedicine复方投稿需要提供指纹图谱吗,没有怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=468e9243712, createdName=ms8000002041881019, createdTime=Tue Apr 09 10:23:45 CST 2024, time=2024-04-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2126674, encodeId=3a3521266e454, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:中药复方;代谢病<br>经验分享:2023.02.25 submit<br>2023.03.03 under editor assessment<br>2023.03.09 under review<br>2023.03.19 required reviews completed<br>2023.03.25 revise,审稿人意见都比较积极,算是小修、润色、降重。给了20天修回。<br>2023.04.12 返回<br>2023.04.17 under editor assessment<br>2023.04.18 reviewer invited<br>目前是这种状态,后续再更新状态。<br><br>希望能够顺利接收,总体来讲,审稿人如果审的快的话一个月就可以完成。<br>编辑和杂志都不错,效率其实还行。<br><br>希望能赶在毕业前接收~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54158562904, createdName=ms2000000770833142, createdTime=Tue Apr 18 09:45:29 CST 2023, time=2023-04-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2131405, encodeId=6236213140557, content=想要询问一下以下情况如何解决:<br><br>(X) Author agreement<br>(has to be uploaded as an extra file; Format: MS Word, TIF, EPS, … (not .pdf please!))<br>The author agreement form for this journal with all author signatures is required. The signature of corresponding author is mandatory.<br>(https://www.elsevier.com/__data/promis_misc/710660_aucc_author_agreement.pdf)<br>(X) Format: Acceptable text file formats include MS Word, Word Perfect, RTF, TEX or plain ASCII text. TIF and EPS files are preferred for figures. PDF, DVI and PS files are not acceptable for publishing purposes.<br>(X) Figure legends. Only text; before figures<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57318663160, createdName=ms1000001447770011, createdTime=Wed May 10 14:57:44 CST 2023, time=2023-05-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2130918, encodeId=df56213091879, content=咨询大家一下,投稿出现这些问题,要如何处理呢?<br><br>(X)Figure legends. Only text; before figures<br><br>(X) Figures separately, also at the end of the manuscript have to be uploaded as an extra file (Format: TIF, EPS) without legends<br><br>(X) Reference list according to our journal style.<br>--&gt; In alphabetical order without numbers<br>--&gt; with ABBREVIATED journal titles.<br>(ex. Goto, N., Ueo, T., Fukuda, A., Kawada, K., Sakai, Y., Miyoshi, H., Taketo, M.M., Chiba, T., Seno, H., 2017. Distinct roles of HES1 in normal stem cells and tumor stem-like cells of the intestine. Cancer Res. 77 (13), 3442-3454.)<br><br>(X) All citations in the text should refer to:<br>1. Single author: the author's name (without initials, unless there is ambiguity) and the year of publication;<br>2. Two authors: both authors' names and the year of publication;<br>3. Three or more authors: first author's name followed by 'et al.' and the year of publication.<br>Citations may be made directly (or parenthetically). Groups of references should be listed first alphabetically, then chronologically.<br>Examples: 'as demonstrated (Allan, 2000a, 2000b, 1999; Allan and Jones, 1999).(Kramer et al.,2010). Kramer et al. (2010) have recently shown .…'<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b168663492, createdName=ms7000000863199411, createdTime=Mon May 08 09:20:15 CST 2023, time=2023-05-08, status=1, ipAttribution=江西省)]
    2023-05-08 ms7000000863199411 来自江西省

    咨询大家一下,投稿出现这些问题,要如何处理呢?

    (X)Figure legends. Only text; before figures

    (X) Figures separately, also at the end of the manuscript have to be uploaded as an extra file (Format: TIF, EPS) without legends

    (X) Reference list according to our journal style.
    --> In alphabetical order without numbers
    --> with ABBREVIATED journal titles.
    (ex. Goto, N., Ueo, T., Fukuda, A., Kawada, K., Sakai, Y., Miyoshi, H., Taketo, M.M., Chiba, T., Seno, H., 2017. Distinct roles of HES1 in normal stem cells and tumor stem-like cells of the intestine. Cancer Res. 77 (13), 3442-3454.)

    (X) All citations in the text should refer to:
    1. Single author: the author's name (without initials, unless there is ambiguity) and the year of publication;
    2. Two authors: both authors' names and the year of publication;
    3. Three or more authors: first author's name followed by 'et al.' and the year of publication.
    Citations may be made directly (or parenthetically). Groups of references should be listed first alphabetically, then chronologically.
    Examples: 'as demonstrated (Allan, 2000a, 2000b, 1999; Allan and Jones, 1999).(Kramer et al.,2010). Kramer et al. (2010) have recently shown .…'

    4

    展开4条回复
共500条页码: 1/50页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分